…
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-free therapy for horses, cats, and dogs that reduces swelling and pain, as well as heals muscle and tendon injuries, sores, and incisions. It sells its products to wholesale distributors, hospitals and clinics, and consumers. The company was incorporated in 2000 and is headquartered in Frederick, Maryland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
BioElectronics Corp develops and sells non‑invasive, low‑level electrical stimulation devices for consumer and select clinical use to manage pain. Long‑term drivers are demand for non‑opioid pain options, expansion of direct‑to‑consumer and international sales, and product development, which may support its long‑term outlook.
Key risks include limited public disclosure and thin trading on the Pink market, reliance on a narrow product portfolio with regulatory and execution uncertainty, and competition from larger device makers and pharmacologic alternatives.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -0.93M | -0.72M | -0.78M | - | - |
| Net income | -0.93M | -0.72M | -0.78M | - | - |
| Gross profit | 0.36M | 0.47M | 0.49M | - | - |
| Ebit | - | -0.44M | -0.57M | -0.14M | -1.03M |
| Ebitda | -0.39M | -0.27M | -0.34M | - | - |
| Depreciation and amortization | - | 0.17M | 0.23M | - | - |
| Operating income | -0.39M | -0.27M | -0.34M | - | - |
| Other operating expenses | 0.89M | 0.99M | 1.05M | - | - |
| Interest expense | 0.54M | 0.45M | 0.44M | 0.00M | 0.00M |
| Income tax expense | - | -0.17M | -0.23M | - | - |
| Total revenue | 0.50M | 0.71M | 0.71M | - | - |
| Total operating expenses | 0.76M | 0.74M | 0.83M | - | - |
| Cost of revenue | 0.13M | 0.25M | 0.22M | - | - |
| Total other income expense net | -0.54M | -0.45M | -0.44M | - | - |
| Net income applicable to common shares | - | - | - | -0.29M | -1.16M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 0.04M | 0.14M | 0.25M | - | - |
| Other current assets | - | - | 0.00M | - | - |
| Total liab | 17.45M | 16.62M | 16.01M | - | - |
| Total stockholder equity | -17.41M | -16.48M | -15.76M | - | - |
| Other current liab | 0.79M | 0.78M | 0.93M | 0.58M | 1.00M |
| Common stock | 23.34M | 23.34M | 23.34M | 24.38M | 24.13M |
| Retained earnings | -40.74M | -39.81M | -39.09M | -38.31M | -38.25M |
| Cash | 0.01M | 0.00M | 0.05M | - | - |
| Total current liabilities | 3.96M | 4.09M | 3.81M | 5.93M | 8.84M |
| Current deferred revenue | 0.10M | 0.21M | 0.25M | - | - |
| Net debt | 15.52M | 14.83M | 14.04M | - | - |
| Short term debt | 2.04M | 2.30M | 1.90M | - | - |
| Short long term debt total | 15.53M | 14.83M | 14.09M | - | - |
| Other stockholder equity | - | 0.00M | -23.34M | -1.19M | -1.01M |
| Total current assets | 0.04M | 0.14M | 0.25M | 0.08M | 0.43M |
| Net tangible assets | - | - | - | -15.12M | -15.12M |
| Net receivables | 0.00M | 0.10M | 0.08M | 0.06M | 0.16M |
| Inventory | 0.03M | 0.04M | 0.13M | 0.03M | 0.15M |
| Accounts payable | 1.03M | 0.80M | 0.74M | 0.65M | 0.73M |
| Accumulated other comprehensive income | - | - | 23.34M | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Change to liabilities | - | - | - | -0.51M | 0.25M |
| Net borrowings | - | - | - | 0.32M | 0.72M |
| Total cash from financing activities | 0.17M | 0.30M | 0.52M | 0.21M | 0.59M |
| Change to operating activities | - | - | - | - | 0.01M |
| Net income | -0.93M | -0.72M | -0.23M | -0.29M | -1.16M |
| Change in cash | 0.00M | -0.04M | 0.04M | -0.11M | 0.06M |
| Begin period cash flow | 0.00M | 0.05M | 0.00M | - | - |
| End period cash flow | 0.01M | 0.00M | 0.05M | - | - |
| Total cash from operating activities | -0.16M | -0.34M | -0.48M | -0.32M | -0.53M |
| Change to inventory | 0.01M | 0.09M | -0.10M | 0.13M | -0.05M |
| Change to account receivables | 0.09M | -0.07M | -0.02M | 0.11M | 0.01M |
| Other cashflows from financing activities | - | 0.30M | 0.52M | -0.11M | -0.13M |
| Change to netincome | - | - | - | 0.25M | 0.42M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.23M | -0.11M | -0.06M | - | - |
| Other non cash items | 0.54M | 0.50M | -0.19M | - | - |
| Free cash flow | -0.16M | -0.34M | -0.48M | - | - |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| BIEL Bioelectronics Corp |
0.00 50.00% |
0.00 | - | - | 6.14 | - |
| ABT Abbott Laboratories |
-0.20 0.19% |
103.00 | 25.97 | 17.24 | 3.57 | 3.20 |
| MDT Medtronic PLC |
-0.59 0.59% |
100.02 | 26.60 | 15.87 | 3.35 | 2.08 |
| SYK Stryker Corporation |
- -% |
310.00 | 29.23 | 16.86 | 4.18 | 4.51 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 |
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-free therapy for horses, cats, and dogs that reduces swelling and pain, as well as heals muscle and tendon injuries, sores, and incisions. It sells its products to wholesale distributors, hospitals and clinics, and consumers. The company was incorporated in 2000 and is headquartered in Frederick, Maryland.
| Name | Title | Year Born |
|---|---|---|
| Mr. Andrew J. Whelan | Founder | 1942 |
| Ms. Kelly A. Whelan | CEO, Pres, Treasurer & Exec. Director | NA |
| Mr. Keith E. Nalepka | VP of Sales & Marketing and Exec. Director | 1974 |
| John R. Martinez | Sec. & VP of Engineering | NA |
| Ms. Kelly A. Whelan | CEO, President, Treasurer & Executive Director | NA |
| Mr. Keith E. Nalepka | VP of Sales & Marketing and Executive Director | 1974 |
| Mr. John R. Martinez | Secretary & VP of Engineering | NA |
| Mr. John R. Martinez | Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.